Abstract:Nuclear factor erythroid 2-related factor 1 (NFE2L1, also known as NRF1), a ubiquitously expressed CNC-bZIP protein, is an important regulator of the antioxidant response, proteasome homeostasis, genetic stability, mitochondrial respiration, inflammation, lipid metabolism and cell differentiation. Recently, we found that silencing of Nfe2l1 in pancreatic beta-cells, led to a phenotype markedly resembling pre-T2D conditions with disrupted glucose metabolism and impaired insulin secretion. The impaired glucose responsiveness due to Nfe2l1 silencing are likely a result of aberrant expression of a group of glucose metabolic enzymes. The findings demonstrated an important role of NRF1 in regulating glucose metabolism and insulin secretion in pancreatic beta-cells and characterized NRF1 as a key transcription factor that regulates the coupling between glycolysis and mitochondrial metabolism and insulin secretion. In addition, we examined the tumorigenicity of Nfe2l1 deficient insulinoma MIN6 cells (Nfe2l1-KD) and their sensitivity to chemotherapy. We found that Nfe2l1-KD insulinoma cells grew faster and were more aggressive than Scramble cells in vitro. Insulinoma arising from Nfe2l1-KD cells in an allograft transplantation mouse model was more aggressive and chemo-resistant. This conclusion was confirmed by streptozotocin (STZ) administration in an allograft transplantation model in diabetic Akita background mouse. In addition, we found that Nfe2l1-KD cells were resistant to chemotherapeutic drugs STZ and 5-fluorouracil-induced damage, which was linked to binding of hexokinase 1 with mitochondria, enhancing mitochondrial membrane potential and closing mitochondrial potential transition pore. Overall, both in vitro and in vivo data from Nfe2l1-KD MIN6 insulinoma cells indicate a previously un-appreciated action of NRF1 in suppression of tumorigenesis and sensitizes cells and their derivative tumors to chemotherapeutic-induced damage and apoptosis, likely via metabolic reprograming. These data indicate that NRF1 could potentially play an important role in the carcinogenic process and impact chemotherapeutic efficacy, at least within a subset of pancreatic endocrine tumors.

Regulatory Role of CNC-bZIP Protein NRF1 in Metabolic Homeostasis of Pancreatic beta-cells and Chemo-sensitivity of Insulinoma Cells

Nfe2l1-silenced Insulinoma Cells Acquire Aggressiveness and Chemoresistance.

Cnc-Bzip Protein Nrf1-Dependent Regulation of Glucose-Stimulated Insulin Secretion

The High NRF2 Expression Confers Chemotherapy Resistance Partly Through Up-Regulated DUSP1 in Myelodysplastic Syndromes

Protective Role of Nuclear Factor E2-Related Factor 2 Against Acute Oxidative Stress-Induced Pancreatic Β -Cell Damage.

Silencing of NRF2 Reduces the Expression of ALDH1A1 and ALDH3A1 and Sensitizes to 5-FU in Pancreatic Cancer Cells

Interplay Of Mkp-1 And Nrf2 Drives Tumor Growth And Drug Resistance In Non-Small Cell Lung Cancer

Silencing of NAC1 Expression Induces Cancer Cells Oxidative Stress in Hypoxia and Potentiates the Therapeutic Activity of Elesclomol.

NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis

Nrf1 is Endowed with a Dominant Tumor-Repressing Effect Onto the Wnt/β-Catenin-Dependent and Wnt/β-Catenin-Independent Signaling Networks in the Human Liver Cancer

Non-canonical NRF2 activation promotes a pro-diabetic shift in hepatic glucose metabolism

Regulatory Role of KEAP1 and NRF2 in PPARγ Expression and Chemoresistance in Human Non-Small-cell Lung Carcinoma Cells.

Genetic Loss of Nrf1 and Nrf2 Leads to Distinct Metabolism Reprogramming of HepG2 Cells by Opposing Regulation of the PI3K-AKT-mTOR Signalling Pathway.

Impact Of Nrf2 On Tumour Growth And Drug Sensitivity In Oncogenic K-Ras-Transformed Cells In Vitro And In Vivo

Inhibition of the Keap1/Nrf2 Signaling Pathway Significantly Promotes the Progression of Type 1 Diabetes Mellitus

Role of Nuclear Factor (Erythroid-Derived 2)-Like 2 in Metabolic Homeostasis and Insulin Action: A Novel Opportunity for Diabetes Treatment?

Oncogenic Activation of Nrf2, Though As a Master Antioxidant Transcription Factor, Liberated by Specific Knockout of the Full-Length Nrf1α That Acts As a Dominant Tumor Repressor

Nuclear factor-Y mediates pancreatic β-cell compensation by repressing reactive oxygen species-induced apoptosis under metabolic stress

Activation of Nrf2 by Sulforaphane Inhibits High Glucose-Induced Progression of Pancreatic Cancer Via AMPK Dependent Signaling

Nfe2l1 deficiency mitigates streptozotocin-induced pancreatic β-cell destruction and development of diabetes in male mice

Nrf1 is Paved As a New Strategic Avenue to Prevent and Treat Cancer, Neurodegenerative and Other Diseases